132073-82-6

Basic information

• Product Name: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE
• Synonyms: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE;(S)-4-Benzyl-2-(hydroxymethyl)morpholine;(S)-(4-benzylMorpholin-2-yl)Methanol-HCl;(2S)-4-(PhenylMethyl)-2-MorpholineMethanol
• CAS NO: 132073-82-6
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.268880
• Mol File: 132073-82-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 303.2 °C at 760 mmHg
• Flash Point: 137.2 °C
• Appearance: /
• Density: 1.117 g/cm³
• Vapor Pressure: 0.000415mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE(132073-82-6)
• EPA Substance Registry System: (S)-N-BENZYL-2-HYDROXYMETHYLMORPHOLINE(132073-82-6)

Safety Data

• Hazardous Substances Data: 132073-82-6(Hazardous Substances Data)

Usage

General Description

(S)-N-Benzyl-2-hydroxymethylmorpholine is a chemical compound that belongs to the morpholine family, which is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is a chiral compound with a benzyl group attached to the nitrogen atom and a hydroxymethyl group attached to the carbon atom. This chemical compound has been identified as a potential ligand for metal-catalyzed asymmetric transformations. It is also known for its use in the synthesis of diverse bioactive molecules and as a reagent in organic chemistry reactions. Additionally, (S)-N-Benzyl-2-hydroxymethylmorpholine has been studied for its potential application in the development of new drug candidates.

InChI:InChI=1/C12H17NO2/c14-10-12-9-13(6-7-15-12)8-11-4-2-1-3-5-11/h1-5,12,14H,6-10H2/t12-/m0/s1

Upstream product

• 148638-78-2 (S)-4-Benzyl-6-hydroxymethyl-morpholin-3-one 
• 67843-74-7 (S)-epichlorohydrin 
• 104-63-2 N-Benzylethanolamine 
• 109208-40-4 N-benzyl-N-amine 
• 148638-77-1 N-Benzyl-2-chloro-N-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-acetamide 
• 148638-82-8 Acetic acid (R)-3-benzyl-2-oxo-oxazolidin-5-ylmethyl ester 
• 148638-80-6 N-benzyl-N-(tert-butoxycarbonyl)-N-<2(S),3-dihydroxypropyl>amine 
• 148638-79-3 N-benzyl-N-(tert-butoxycarbonyl)-N-amine 
• 148638-81-7 Methanesulfonic acid (S)-2-(benzyl-tert-butoxycarbonyl-amino)-1-methanesulfonyloxymethyl-ethyl ester 
• 135065-72-4 (S)-N-benzyl-3-chloroacetamidopropane-1,2-diol 
• 1022915-29-2 (R)-1-chloro-3-[(2-hydroxyethyl)(phenylmethyl)amino]-2-propanol 
• 51594-55-9 (R)-(-)-epichlorohydrin 
• 100-52-7 benzaldehyde 

Downstream Products

• 1414940-03-6 (S)-1-(indolin-1-yl)-2-(2-(phenoxymethyl)morpholino)ethanone 
• 52520-62-4 (2S)-4-benzyl-2-<<(p-tolylsulfonyl)oxy>methyl>morpholine 
• 661470-52-6 (S)-2-(phenoxymethyl)morpholine 
• 132073-84-8 (S)-4-trityl-2-hydroxymethylmorpholine 
• 135065-62-2 (S)-4-tert-butoxycarbonyl-2-p-nitrobenzenesulfonyloxymethylmorpholine 
• 148638-76-0 tert-butyl (2S)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 132073-83-7 (S)-morpholin-2-ylmethanol 
• 1174913-80-4 tert-butyl (2R)-2-(aminomethyl)morpholine-4-carboxylate 

Relevant articles and documents

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.

Radiosynthesis and evaluation of 18F-labeled dopamine D4-receptor ligands

Introduction: The dopamine D4 receptor (D4R) has attracted considerable attention as potential target for the treatment of a broad range of central nervous system disorders. Although many efforts have been made to improve the performance of putative radioligand candidates, there is still a lack of D4R selective tracers suitable for in vivo PET imaging. Thus, the objective of this work was to develop a D4-selective PET ligand for clinical applications. Methods: Four compounds based on previous and new lead structures were prepared and characterized with regard to their D4R subtype selectivity and predicted lipophilicity. From these, 3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine I and (S)-4-(3-fluoro-4-methoxybenzyl)-2-(phenoxymethyl)morpholine II were selected for labeling with fluorine-18 and subsequent evaluation by in vitro autoradiography to assess their suitability as D4 radioligand candidates for in vivo imaging. Results: The radiosynthesis of [18F]I and [18F]II was successfully achieved by copper-mediated radiofluorination with radiochemical yields of 7% and 66%, respectively. The radioligand [18F]II showed specific binding in areas where D4 expression is expected, whereas [18F]I did not show any uptake in distinct brain regions and exhibited an unacceptable degree of non-specific binding. Conclusions: The compounds studied exhibited high D4R subtype selectivity and logP values compatible with high brain uptake, but only ligand [18F]II showed low non-specific binding and is therefore a good candidate for further evaluation. Advances in knowledge: The discovery of new lead structures for high-affinity D4 ligands opens up new possibilities for the development of suitable PET-radioligands. Implications for patient: PET-imaging of dopamine D4-receptors could facilitate understanding, diagnosis and treatment of neuropsychiatric and neurodegenerative diseases.

Novel Triazolopyrazine Derivatives and Use Thereof

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.